Mucosal administration ................................................ 448
Mutagenesis........................................ 332–334, 337–339,
341, 346, 351, 353
N
Nanoparticles...............................78, 222, 223, 440, 444,
499–501, 507, 510
Needle-free .................................................. 437, 438, 444
Neutralization assays ............................................ 575–584
Neutrophils........................................................... 559–573
N-glycosylation ......................................... 84, 87, 88, 206
Non-covalent................................................................. 478
Non-viral gene delivery .....................................................v
O
O-antigen ............................................................. 267–302
Oligosaccharides.....................................84, 90, 206, 268,
305–311, 314, 315, 327
Online process monitoring............................................. 95
Opsonophagocytic killing.................................... 560, 570
Ovalbumin (OVA) .............................305, 492, 501–503,
513, 514, 526, 528, 529, 534, 550, 551
P
Pathogen-specific plasmablasts .......................... 10, 17, 18
PEGylation ........................................................... 358, 364
Plaque assays................................ 73, 103–105, 110, 111,
116, 223, 346, 348, 349, 372, 380, 417, 577, 582
Plunge freezing .................................................... 501, 504
Pneumococcal disease ................................. 1, 3, 6, 7, 478
Polyacrylamide gel electrophoresis
(PAGE) .....................................74, 309, 316, 318,
319, 321, 326, 468, 481
Polyethylene glycol (PEG) ........................ 221, 222, 358,
359, 392, 479, 490
Polyprenyl-based vaccines............................................. 391
Polysaccharides ................................... 3–6, 250, 252–254,
260, 267, 268, 280, 302, 313–328, 332, 407,
477–486, 559, 560, 568, 571
Process analytical technology ......................................... 95
Process development................................... 119, 131, 576
Protection against lethal challenges ............................... 65
Protein production..............................105, 106, 117, 584
Pseudotyped baculovirus .................................... 370, 372,
376, 382, 385
Purifications ................................................ 52, 66, 69, 75,
76, 84, 87, 89–91, 93, 119–133, 184, 186, 189,
191, 192, 197, 198, 201, 207, 209, 210, 212,
218, 220–223, 234, 236, 267–302, 308, 313,
315, 323, 362, 370–372, 376, 377, 379, 382,
383, 395, 409, 413, 420, 425, 428, 429, 466,
467, 481, 484, 576
R
Rotavirus antigens......................120, 121, 126, 129, 130
S
Salmonella................................... 252–255, 257, 268, 332
Spodoptera frugiperda Sf-9 cells............. 95, 100, 102–105
Steric exclusion...........................221, 222, 235, 236, 371
Stirred tank bioreactor ........................................ 101, 102,
105, 106, 218, 372, 376
Streptococcus pneumoniae .................................... 3, 5, 250,
253, 254, 259, 261, 465, 472, 473, 477, 478,
559–561, 563–565, 568–573
Structural proteins ............................................... 184, 424
Subviral particles (SVPs)............................. 84, 85, 92, 93
T
Tangential flow filtration (TFF) ......................... 239, 270,
276, 277, 302, 371, 372, 374, 379, 380, 491–497
T cell killing .......................................................... 551, 558
TCID50.......................................78, 103, 105, 110, 111,
115, 116, 219, 233, 346–348, 372, 380,
575–577, 582
Thin-film freezing (TFF) ............................ 491, 493, 494
T lymphocyte................................................................... 20
Tomography ........................................501, 506, 508–510
Transfections ........................................ 64, 68–72, 84, 86,
88–90, 92, 102, 109, 110, 115, 116, 196, 197,
199, 202, 219, 343, 346, 398, 402
Trimethylpolyprenylammonium iodides
(PTAI)............................. 392–394, 396–399, 401
U
Upstream processing..........................218, 219, 224–226,
230–233, 238, 370
V
Vacceed .......................................................................29–41
Vaccine antigen discovery ................................................. 9
Vaccine delivery .................................. 1–7, 392, 423–435,
438, 439, 444, 445, 499
Vaccine delivery carriers ....................................... 499–511
Vaccines........................................ 1–7, 10, 19–21, 29, 30,
33, 34, 43–47, 51, 52, 54, 56–58, 64, 76–78, 83,
84, 95, 184, 205, 206, 217–244, 249–261, 267,
268, 331–353, 368, 369, 371, 391–395, 397,
399, 402, 403, 405–408, 412, 424, 425, 428,
431, 433, 437–441, 444, 445, 448, 461, 462,
477, 478, 485, 486, 489–497, 502, 513–523,
525, 526, 529, 534, 537, 538, 545, 549–551,
556, 559–561, 563, 568, 570, 571, 575, 576
Viral infectivity ..................................................... 575–584
Viral titration ................................................................. 347
VACCINE DELIVERY TECHNOLOGY: METHODS AND PROTOCOLS
Index 589
Mutagenesis........................................ 332–334, 337–339,
341, 346, 351, 353
N
Nanoparticles...............................78, 222, 223, 440, 444,
499–501, 507, 510
Needle-free .................................................. 437, 438, 444
Neutralization assays ............................................ 575–584
Neutrophils........................................................... 559–573
N-glycosylation ......................................... 84, 87, 88, 206
Non-covalent................................................................. 478
Non-viral gene delivery .....................................................v
O
O-antigen ............................................................. 267–302
Oligosaccharides.....................................84, 90, 206, 268,
305–311, 314, 315, 327
Online process monitoring............................................. 95
Opsonophagocytic killing.................................... 560, 570
Ovalbumin (OVA) .............................305, 492, 501–503,
513, 514, 526, 528, 529, 534, 550, 551
P
Pathogen-specific plasmablasts .......................... 10, 17, 18
PEGylation ........................................................... 358, 364
Plaque assays................................ 73, 103–105, 110, 111,
116, 223, 346, 348, 349, 372, 380, 417, 577, 582
Plunge freezing .................................................... 501, 504
Pneumococcal disease ................................. 1, 3, 6, 7, 478
Polyacrylamide gel electrophoresis
(PAGE) .....................................74, 309, 316, 318,
319, 321, 326, 468, 481
Polyethylene glycol (PEG) ........................ 221, 222, 358,
359, 392, 479, 490
Polyprenyl-based vaccines............................................. 391
Polysaccharides ................................... 3–6, 250, 252–254,
260, 267, 268, 280, 302, 313–328, 332, 407,
477–486, 559, 560, 568, 571
Process analytical technology ......................................... 95
Process development................................... 119, 131, 576
Protection against lethal challenges ............................... 65
Protein production..............................105, 106, 117, 584
Pseudotyped baculovirus .................................... 370, 372,
376, 382, 385
Purifications ................................................ 52, 66, 69, 75,
76, 84, 87, 89–91, 93, 119–133, 184, 186, 189,
191, 192, 197, 198, 201, 207, 209, 210, 212,
218, 220–223, 234, 236, 267–302, 308, 313,
315, 323, 362, 370–372, 376, 377, 379, 382,
383, 395, 409, 413, 420, 425, 428, 429, 466,
467, 481, 484, 576
R
Rotavirus antigens......................120, 121, 126, 129, 130
S
Salmonella................................... 252–255, 257, 268, 332
Spodoptera frugiperda Sf-9 cells............. 95, 100, 102–105
Steric exclusion...........................221, 222, 235, 236, 371
Stirred tank bioreactor ........................................ 101, 102,
105, 106, 218, 372, 376
Streptococcus pneumoniae .................................... 3, 5, 250,
253, 254, 259, 261, 465, 472, 473, 477, 478,
559–561, 563–565, 568–573
Structural proteins ............................................... 184, 424
Subviral particles (SVPs)............................. 84, 85, 92, 93
T
Tangential flow filtration (TFF) ......................... 239, 270,
276, 277, 302, 371, 372, 374, 379, 380, 491–497
T cell killing .......................................................... 551, 558
TCID50.......................................78, 103, 105, 110, 111,
115, 116, 219, 233, 346–348, 372, 380,
575–577, 582
Thin-film freezing (TFF) ............................ 491, 493, 494
T lymphocyte................................................................... 20
Tomography ........................................501, 506, 508–510
Transfections ........................................ 64, 68–72, 84, 86,
88–90, 92, 102, 109, 110, 115, 116, 196, 197,
199, 202, 219, 343, 346, 398, 402
Trimethylpolyprenylammonium iodides
(PTAI)............................. 392–394, 396–399, 401
U
Upstream processing..........................218, 219, 224–226,
230–233, 238, 370
V
Vacceed .......................................................................29–41
Vaccine antigen discovery ................................................. 9
Vaccine delivery .................................. 1–7, 392, 423–435,
438, 439, 444, 445, 499
Vaccine delivery carriers ....................................... 499–511
Vaccines........................................ 1–7, 10, 19–21, 29, 30,
33, 34, 43–47, 51, 52, 54, 56–58, 64, 76–78, 83,
84, 95, 184, 205, 206, 217–244, 249–261, 267,
268, 331–353, 368, 369, 371, 391–395, 397,
399, 402, 403, 405–408, 412, 424, 425, 428,
431, 433, 437–441, 444, 445, 448, 461, 462,
477, 478, 485, 486, 489–497, 502, 513–523,
525, 526, 529, 534, 537, 538, 545, 549–551,
556, 559–561, 563, 568, 570, 571, 575, 576
Viral infectivity ..................................................... 575–584
Viral titration ................................................................. 347
VACCINE DELIVERY TECHNOLOGY: METHODS AND PROTOCOLS
Index 589